 MONTREAL, July 06, 2021 GLOBE NEWSWIRE -- Knight Therapeutics Inc. TSX: GUD, Knight a pan-American ex-USA specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX neratinib in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressedamplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The approval was based on results of the global Phase III NALA trial. Knight has the exclusive right to commercialize NERLYNX in Canada under the terms of a license agreement entered into with Puma Biotechnology, Inc. NASDAQ: PBYI. 